Verve Therapeutics’ next-generation gene editing treatment lowered cholesterol levels in a handful of patients with heterozygous familial hypercholesterolemia, marking the first time that base editing has been used to directly alter DNA in humans.
The early Phase I data, presented Sunday at the American Heart Association’s…
Click here to view original post
